Navigation Links
Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease
Date:6/9/2008

Potential Efficacy in Huntington's Disease Already Demonstrated

NOVATO, Calif., June 9 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that the U.S. Food and Drug Administration ("FDA") has granted orphan drug designation for cysteamine bitartrate ("cysteamine") for the treatment of Huntington's disease ("HD"). Cysteamine is currently approved by the FDA and European Medicines Agency ("EMEA") to treat nephropathic cystinosis ("cystinosis"), a rare lysosomal storage disease. Preclinical results suggest that cysteamine has neuroprotective effects that could potentially help treat HD. Raptor's clinical development subsidiary, Bennu Pharmaceuticals Inc. ("Bennu"), plans to evaluate cysteamine in patients with HD.

HD is a rare and hereditary neurological disease thought to occur in approximately 1 out of every 20,000 people resulting in around 20,000 patients in the U.S. presently. There is currently no drug available that targets the unique molecular defect that is believed to cause HD, a progressive disease that often leads to death within 15 to 20 years after diagnosis. HD is caused by a defective gene resulting in the degeneration of certain nerve cells in the brain. The disease is characterized by uncontrollable movements and mood swings or depression, followed by dementia. Preclinical findings on cysteamine's mechanism of action suggest that it has neuroprotective effects by increasing the levels of BDNF, a neuroprotective neurotrophic factor, in the brain of HD mice. BDNF levels may also be a potential biomarker of efficacy for cysteamine in HD, an important development issue when a therapy is used to prevent or slow clinical manifestation of a disorder.

The 1983 Orphan Drug Act provides important economic incentives to encourage companies to develop potential therapies for the diagnosis, prevention and/or treatment of rare, serious diseases affecting 200,0
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Acquires Orphan Clinical Program
2. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Hills, MI (PRWEB) May 05, 2015 ... premier Parker Hannifin distributor, announces the launch of ... provide fleet operators with a convenient way to ... maintenance products . , The new ... to 100,000 vehicles with direct access to high ...
(Date:5/4/2015)... Many of us take a healthy ... with rare, inherited mutations of certain genes, severe ... impaired immune responses. Now, researchers at ... role for calcium signaling in immune responses to ... causing tuberculosis (TB). Specifically, they ...
(Date:5/4/2015)... May 4, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on Form 20-F for the fiscal year ended December ... ("SEC"). The annual report on Form 20-F contains information ... in the area of cancer immune checkpoints. This project ... high specificity and binding in targeting certain identified immune ...
(Date:5/4/2015)... Genedata, a leading provider of advanced ... research, today announced the release of Genedata ... enterprise solution for biologics R&D. This first-in-class workflow ... and development of novel biotherapeutics. Version 5.0 enables ... optimization and developability requirements. Genedata will present highlights ...
Breaking Biology Technology:Exotic Automation & Supply Launches Ecommerce Website 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4
... Rocky Mountain Biosystems, Inc.(R),(RMBI), a Denver ... a,grant award of approximately $600,000 over two ... Infectious Diseases at the National Institutes of,Health ... technology for influenza vaccination. In the event ...
... Corporation, Joins Board of Directors, Ron ... Myers Appointed Vice President Legal Affairs -, SEATTLE, ... on the development of therapeutics for,autoimmune and inflammatory disorders, ... scientific officer of Dendreon Corporation,(Nasdaq: DNDN ), to ...
... GAITHERSBURG, Md., Feb. 13 Lentigen Corporation ... headquarters and,manufacturing facilities from the University of ... square-foot facility in Gaithersburg., Located along ... accommodate Lentigen,s future growth needs as a ...
Cached Biology Technology:NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza 2VLST Corporation Announces Board and Executive Management Appointments 2VLST Corporation Announces Board and Executive Management Appointments 3Lentigen to Move Headquarters and Manufacturing to Gaithersburg 2
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/13/2015)... 13, 2015  higi, a leading cloud-based consumer engagement ... fully engage with their communities around health and wellness, ... and secure API.  ... accessible, affordable, and convenient vehicle to receive validated health ... The API will allow higi,s trusted partners, ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... in war zones and farmers tending their fields can have ... In large doses these agents, called organophosphates, are proven, ... chronic disabilities such as problems with learning and memory, headaches ... at the Medical College of Georgia at Georgia Health Sciences ...
... Institute of Standards and Technology (NIST) and the University ... that engineered nanoparticles are able to accumulate within plants ... team led by NIST chemist Bryant C. Nelson showed ... capacity to enter plant root cells and generate many ...
... (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have ... into patients with diabetes who are suffering from critical ... complication of diabetes. The team of researchers in Seville, ... in a recent issue of Cell Transplantation ...
Cached Biology News:Effect of chronic exposure to chemicals used as weapons, pesticides under study 2Effect of chronic exposure to chemicals used as weapons, pesticides under study 3NIST/UMass study finds evidence nanoparticles may increase plant DNA damage 2Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations 2